Focus: Gossamer Bio is a San Diego-based small-molecule biotech focused on immunology and oncology with a diversified pipeline across respiratory, cardiovascular, GI, and CNS indications. The company is in clinical-stage development with 12 active trials spanning Phase 1–3.
Profile data last refreshed 13h ago · AI intelligence enriched 2mo ago
High-risk, high-reward opportunity best suited for candidates with tolerance for clinical volatility and restructuring; pipeline depth is real but recent layoffs signal survival mode.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Gossamer Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Gossamer Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Fierce Biotech Layoff Tracker 2026: Sionna halves staff; Merck trims more NJ jobs - Fierce Biotech
Fierce Biotech Layoff Tracker 2026: Sionna halves staff; Merck trims more NJ jobs Fierce Biotech
Gossamer Bio announces $250m in funding to advance seralutinib - Pharmaceutical Technology
Gossamer Bio announces $250m in funding to advance seralutinib Pharmaceutical Technology
Gossamer Bio Raises Up to $250 Million in Milestone-Linked Financing Ahead of Seralutinib FDA Filing - finance.biggo.com
Gossamer Bio Raises Up to $250 Million in Milestone-Linked Financing Ahead of Seralutinib FDA Filing finance.biggo.com
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update Business Wire
New Drug Prevents Worsening Pulmonary Arterial Hypertension in Major Trial Win - MedPage Today
New Drug Prevents Worsening Pulmonary Arterial Hypertension in Major Trial Win MedPage Today
Cary company ends $160M drug collaboration - The Business Journals
Cary company ends $160M drug collaboration The Business Journals
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent massive layoff is the defining career risk; company is in survival/restructuring mode with heightened job security uncertainty and potential for future cuts if Seralutinib Phase 3 underperforms.